This strategy has achieved clinical practice on a phase I clinical trial by Zhang et al. (2023) were they evaluated the efficacy of naturally CD7 negative anti-CD7 CAR-T cells to treat CD7 positive AML patients. This evidence concerns the gene CD7 and acute myeloid leukemia.